. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Mol Cancer Ther. 2015 Jul 23;14(10):2374–2381. doi: 10.1158/1535-7163.MCT-15-0121

Table 3A.

Results for FOLFIRI plus cetuximab treated patients (n= 153)

SNP	Genotype (N)	ORR (%)	p^*	PFS months	p^**	HR	OS months	p^**	HR
rs895374	CC (55)	76.6	0.94	7.9	0.018		38.3	0.84
	AC (75)	79.0		12.2		0.62	33.1		1.0
	AA (23)	76.2		12.7		0.57	49.8		0.83

rs379464	CC (10)	60.0	0.07	7.8	0.59		39.4	0.96
	CT (45)	90.0		12.2		1.4	33.8		1.1
	TT (83)	77.3		12.8		1.1	38.4		0.98

rs7051590	CC (116)	78.4	0.49	10.6	0.37		36.4	0.31
	CG (7)	71.4		13.3		1.7	41.3		2.1
	GG (14)	91.7		14.1		1.8	58.5		2.6

rs2511837	CC (23)	75.0	0.38	12.9	0.58		41.0	0.72
	CT (67)	75.9		11.3		0.80	36.4		0.71
	TT (48)	86.8		10.6		0.82	33.1		0.92

rs17567	CC (5)	100	0.73	10.4	0.75		18.6	0.61
	CT (49)	78.0		13.1		1.2	36.4		1.8
	TT (88)	80.8		10.0		0.88	38.3		1.1